Cytovance Biologics News and Activities

Cytovance Biologics is owned by Shenzhen Hepalink Pharma.

Shenzhen Hepalink Pharma is a company listed under the stock ticker 002399 (CN).

Shenzhen Hepalink Pharma has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

View the org chart displaying its 11 main executives

Most searched biographies at Cytovance Biologics

• Ping Zhang, Chief Executive Officer
• Brent Van Rite, Senior Director of Manufacturing
• Eric Bell, Senior Director of Quality

Create your alert
to follow the executive moves at Cytovance Biologics.

Shenzhen Hepalink Pharma has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Cytovance Biologics

Social media about Cytovance Biologics

• Cytovance Biologics on Wikipedia, Google News & Yahoo Finance
• Cytovance Biologics on LinkedIn, X (Twitter) & YouTube